S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
1907, 1929, 1998, 2007--and now 2023? (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
1907, 1929, 1998, 2007--and now 2023? (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
1907, 1929, 1998, 2007--and now 2023? (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
1907, 1929, 1998, 2007--and now 2023? (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches

Xilio Therapeutics (XLO) Earnings Date, Estimates & Call Transcripts

$0.72
+0.01 (+1.41%)
(As of 03/1/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

XLO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

XLO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Xilio Therapeutics Analyst EPS Estimates

Current Year EPS Consensus Estimate:($2.76) EPS
Next Year EPS Consensus Estimate: ($1.89) EPS

XLO Earnings Date and Information

Xilio Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 based off prior year's report dates.

Xilio Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/7/2024
Estimated)
------- 
11/9/2023Q3 2023($0.76)($0.61)+$0.15($0.61)--
8/14/2023Q2 2023($0.84)($0.70)+$0.14($0.70)--
5/9/2023Q1 2023($0.91)($0.83)+$0.08($0.83)--
3/2/2023Q4 2022($0.83)($0.82)+$0.01($0.82)--
11/9/2022Q3 2022($0.89)($0.72)+$0.17($0.72)--
8/9/2022Q2 2022($0.78)($0.90)($0.12)($0.90)--
5/12/2022Q1 2022($1.00)($0.78)+$0.22($0.78)--
3/1/2022Q4 2021($0.94)($0.98)($0.04)($0.98)--
12/1/2021Q3 2021($1.60)($21.27)($19.67)($21.27)--












Xilio Therapeutics Earnings - Frequently Asked Questions

When is Xilio Therapeutics's earnings date?

Xilio Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 based off last year's report dates. Learn more on XLO's earnings history.

How much profit does Xilio Therapeutics generate each year?

Xilio Therapeutics (NASDAQ:XLO) has a recorded net income of -$88.22 million. XLO has generated -$2.96 earnings per share over the last four quarters.

What is Xilio Therapeutics's EPS forecast for next year?

Xilio Therapeutics's earnings are expected to grow from ($2.76) per share to ($1.89) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:XLO) was last updated on 3/2/2024 by MarketBeat.com Staff